Gene expression profiling in the prediction of response of multiple myeloma to the proteasome inhibitor PS-341.

被引：0
|
作者：
Shaughnessy, J [1 ]
Zhan, FH [1 ]
McCastlain, K [1 ]
Tian, EM [1 ]
Tricot, G [1 ]
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1512
引用
收藏
页码：390A / 390A
页数：1
相关论文
共 50 条
  • [1] Clinical pharmacology of the proteasome inhibitor PS-341.
    Nix, DJ
    Pien, C
    Labutti, J
    Madden, T
    Adams, J
    Elliott, P
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3732S - 3732S
  • [2] Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341.
    Hideshima, T
    Mitsiades, C
    Akiyama, M
    Hayashi, T
    Chauhan, D
    Richardson, PG
    Schlossman, RL
    Podar, K
    Munshi, NC
    Mitsiades, N
    Anderson, KC
    BLOOD, 2002, 100 (11) : 814A - 814A
  • [3] A phase I pharmacodynamic study of the proteasome inhibitor PS-341.
    Thomas, JP
    Adjei, A
    Ehrlichman, C
    Geiger, P
    Haas, A
    Arzoomanian, R
    Alberti, D
    Marnocha, R
    Binger, K
    Volkman, J
    Feierabend, C
    Tutsch, K
    Adams, J
    Eliot, P
    Wilding, G
    CLINICAL CANCER RESEARCH, 2000, 6 : 4549S - 4549S
  • [4] PROTEASOME INHIBITOR TREATMENT RESPONSE CAN BE PREDICTED BY GENE EXPRESSION PROFILING IN MULTIPLE MYELOMA
    Van Vliet, M. H.
    Kuiper, R.
    Broijl, A.
    Van Duin, M.
    de Best, L.
    van Beers, E. H.
    Sonneveld, P.
    HAEMATOLOGICA, 2014, 99 : 494 - 495
  • [5] The proteasome inhibitor PS-341 modulates VEGF secretion and activity in multiple myeloma.
    Mitsiades, N
    Mitsiades, CS
    Poulaki, V
    Fanourakis, G
    Chauhan, D
    Munshi, NC
    Hideshima, T
    Anderson, KC
    BLOOD, 2002, 100 (11) : 815A - 815A
  • [6] The Hsp90 inhibitor 17-AAG sensitizes human leukemia cells to proteasome inhibitor PS-341.
    Yao, Q
    Kersey, JH
    BLOOD, 2003, 102 (11) : 622A - 623A
  • [7] Creation of a Gene Expression Signature-Based Prediction Model Specific to Proteasome Inhibitor Response in Multiple Myeloma
    Mitra, Amit Kumar
    Mukherjee, Ujjal
    Harding, Taylor
    Chatterjee, Snigdhansu
    Van Ness, Brian G.
    BLOOD, 2015, 126 (23)
  • [8] Transcriptional gene expression profiles in drub-sensitive and bcl-2 resistant myeloma cells in response to dexamethasone, arsenic trioxide and PS-341.
    Feinman, R
    Aris, VM
    Vergano, S
    Galante, AT
    Soteropoulos, P
    Gangurde, P
    Siegel, DS
    Adams, J
    Elliott, PJ
    Tolias, PP
    BLOOD, 2001, 98 (11) : 368A - 368A
  • [9] PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies.
    Stinchcombe, TE
    Mitchell, BS
    Depcik-Smith, N
    Adams, J
    Elliott, P
    Shea, TC
    Orlowski, RZ
    BLOOD, 2000, 96 (11) : 516A - 516A
  • [10] The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
    Ma, MH
    Yang, HH
    Parker, K
    Manyak, S
    Friedman, JM
    Altamirano, C
    Wu, ZQ
    Borad, MJ
    Frantzen, M
    Roussos, E
    Neeser, J
    Mikail, A
    Adams, J
    Sjak-Shie, N
    Vescio, RA
    Berenson, JR
    CLINICAL CANCER RESEARCH, 2003, 9 (03) : 1136 - 1144
12345